Noble Financial analyst Gregory Aurand maintained a Buy rating on Baudax Bio (BXRX – Research Report) today and set a price target of $10.00. The company's shares closed last Wednesday at $1.74, close to its 52-week low of $1.49. According to TipRanks.com, Aurand is ranked #7424 out of 7905 analysts. Baudax Bio has an analyst consensus of Moderate Buy, with a price target consensus of $10.00. See the top stocks recommended by analysts >> The company has a one-year high of $55.30 and a one-year low of $1.49. Currently, Baudax Bio has an average volume of 430.9K.
https://www.tipranks.com/news/blurbs/noble-financial-thinks-baudax-bios-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Baudax Bio Charts.
Baudax Bio (NASDAQ:BXRX)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Baudax Bio Charts.